01—Abstract
Summary
Summary of the 10-Q filed May 8, 2025. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated's first-quarter 2025 Form 10-Q, filed May 8, 2025, shows ARIKAYCE product revenues, net of $92.8 milliona, up 22.9% from $75.5 million a year earlier, with US sales of $64.3 million, Japan $22.1 million, and Europe and rest of world $6.5 million.
Operating expenses rose sharply: R&D reached $152.6 millionb (up 26.0%) and SG&A reached $147.5 million (up 58.5%), with the company citing commercial readiness activities for brensocatib. The operating loss widened to $248.1 million and the net loss to $256.6 million, or $1.42 per share, compared with a net loss of $157.1 million in the prior-year quarter. Cash used in operating activities was $262.1 million for the quarter.
The balance sheet shows cash and cash equivalents of $403.2 millionc and marketable securities of $796.2 million as of March 31, 2025, down from $555.0 million and $878.8 million at year-end 2024. Total shareholders' equity fell to $99.2 million from $285.4 million, and debt, long-term, was $1.11 billion. The company states it has sufficient funds for at least the next 12 months, and it reports that the FDA accepted its brensocatib NDA with priority review and set a PDUFA target action date of August 12, 2025.
The filing also notes that Insmed called its outstanding 2028 Convertible Notes for redemption on April 24, 2025, with a redemption date of June 6, 2025. Key pipeline milestones include TPIP PAH Phase 2b topline results expected in June 2025 and brensocatib CRSsNP Phase 2b topline data expected by the end of 2025.
02—Key points
Key Highlights
- ARIKAYCE product revenues, net, rose 22.9% to $92.8 million for Q1 2025, with growth in the US, Japan, and Europe and rest of world.
- Operating loss widened to $248.1 million from $145.5 million, driven by R&D expenses of $152.6 million (up 26.0%) and SG&A expenses of $147.5 million (up 58.5%).
- Net loss was $256.6 million, or $1.42 per share, versus $157.1 million, or $1.06 per share, in the prior-year quarter.
- Cash and cash equivalents plus marketable securities totaled $1.2 billion at March 31, 2025, down from $1.43 billion at December 31, 2024.
- Total shareholders' equity declined to $99.2 million from $285.4 million, reflecting the net loss.
- The FDA accepted the brensocatib NDA for bronchiectasis with priority review, with a PDUFA target action date of August 12, 2025.
- The company called its 2028 Convertible Notes for redemption on April 24, 2025, with a redemption date of June 6, 2025.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 8, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $92.82M$75.50M | +22.9% |
| Cost of Revenue | $21.28M$17.46M | +21.9% |
| Gross Profit | $71.55M$58.04M | +23.3% |
| R&D Expenses | $152.58M$121.08M | +26.0% |
| SG&A Expenses | $147.54M$93.10M | +58.5% |
| Operating Expenses | $340.96M$221.00M | +54.3% |
| Operating Income | -$248.14M-$145.50M | −70.5% |
| Interest Expense | $21.57M$21.04M | +2.5% |
| Net Income | -$256.58M-$157.09M | −63.3% |
| EPS (Basic) | $-1.42$-1.06 | −34.0% |
| EPS (Diluted) | $-1.42$-1.06 | −34.0% |
| Shares Outstanding (Basic) | 180.86M148.46M | +21.8% |
| Shares Outstanding (Diluted) | 180.86M148.46M | +21.8% |
05—Questions
Frequently Asked Questions
How did Insmed's revenue and losses trend in the first quarter of 2025?
Product revenues, net, increased to $92.8 million from $75.5 million, but operating expenses rose to $341.0 million from $221.0 million. The net loss grew to $256.6 million, or $1.42 per share, from $157.1 million, or $1.06 per share, a year earlier. The company attributed the SG&A increase largely to commercial readiness activities for brensocatib.
How much liquidity does Insmed have, and does the company expect to need more capital?
Cash and cash equivalents were $403.2 million and marketable securities were $796.2 million at March 31, 2025. Cash used in operating activities was $262.1 million in the quarter. The company states it currently has sufficient funds for at least the next 12 months but may raise additional capital in the future, and that its future cash requirements are expected to be substantial.
What regulatory and clinical milestones does the filing identify for the coming months?
The FDA set a PDUFA target action date of August 12, 2025, for brensocatib in bronchiectasis, with a US launch anticipated in the third quarter of 2025 if approved. TPIP Phase 2b PAH topline results are anticipated in June 2025, and BiRCh Phase 2b topline data for CRSsNP are anticipated by the end of 2025.
What changes occurred in the company's debt structure?
Debt, long-term, was $1.11 billion at March 31, 2025. On April 24, 2025, the company called the outstanding 2028 Convertible Notes for redemption with a redemption date of June 6, 2025. The Term Loans carry a fixed 9.6% rate and mature September 30, 2029, subject to acceleration to February 1, 2028, upon certain prespecified events.
Why did shareholders' equity decline so significantly?
Total shareholders' equity fell to $99.2 million from $285.4 million, primarily because of the $256.6 million net loss in the quarter. Stock-based compensation of $39.3 million and proceeds from stock option and ESPP exercises of $29.7 million partially offset the decline in equity.
06—Continue